Year

2016
FOR IMMEDIATE RELEASE: Lexington, MA, December 20, 2016 /PRNewswire    — scPharmaceuticals, Inc., a privately held biopharmaceutical company    developing transformative pharmaceutical products for subcutaneous delivery announced    today that it entered into a long-term commercial supply agreement and associated    tools manufacturing agreement with Raumedic AG (Helmbrechts, Germany) for the    single-use component of its...
Oncolytic virus therapy utilizes modified viruses like the adenovirus (otherwise known as the common cold virus) that selectively replicate within tumor cells and not within normal tissue. Such viruses stimulate an inflammatory response in the tumor microenvironment, resulting in the accumulation of tumor infiltrating lymphocytes. The NG-348 virus uses PsiOxus’ proprietary Tumor-Specific Immunogene Therapy (T-SIGn) platform to “arm” the...
Mr Westberg replaces Offer Nonhoff, who is to leave after four-and-a-half-years with the company. Richard Davies, CEO of BONESUPPORT, said: “I am very pleased to welcome Björn to the BONESUPPORT team. He brings with him a wealth of finance and management experience that I am confident will be crucial to the future growth and development...
BONESUPPORT confirms election of Dr. Håkan Björklund as Chairman of the Board. Tone Kvåle, CFO of Nordic Nanovector, elected as a new Board Member. Lund, Sweden, 16 December 2016 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces, that Dr....
Basel, December 16, 2016 – Novartis announced today that it has entered into a definitive agreement for the acquisition of Ziarco Group Limited, a privately held company focused on the development of novel treatments in dermatology. This acquisition would add a once-daily oral H4 receptor antagonist in development for atopic dermatitis (AD), commonly known as eczema, to complement the...
Richard Davies, CEO of BONESUPPORT, said: “I am very humbled to have been given this award. I firmly believe that BONESUPPORT has an exciting future based on the significant potential of its unique CERAMENT™ platform. This platform is truly innovative and enables surgeons to improve patient outcomes across a range of orthopaedic indications, enabling a...
Hvor længe kan vi leve i fremtiden? Kan vi blot reparere på vores gener i det uendelige? Kan vi ved hjælp af stamceller dyrke nye organer, når de gamle er slidt op? Og er fremtidens medicinske sygdomsbehandling skræddersyet til det enkelte menneske? Hvis man spørger nogle af landets førende forskere, så ligger det rent faktisk...
Vtesse announced early in 2016 that the FDA granted Breakthrough Therapy designation status for VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial in NPC. Both the FDA and the European Medicines Agency (EMA) previously granted Orphan Drug status to VTS-270, and the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted...
Hvor længe kan vi leve i fremtiden? Kan vi blot reparere på vores gener i det uendelige? Kan vi ved hjælp af stamceller dyrke nye organer, når de gamle er slidt op? Og er fremtidens medicinske sygdomsbehandling skræddersyet til det enkelte menneske? Hvis man spørger nogle af landets førende forskere, så ligger det rent faktisk...
The collaboration will combine Bristol-Myers Squibb’s expertise in the discovery and development of novel immunotherapies with Enterome’s proprietary metagenomic technology platform and leadership in the rapidly advancing science of the gut microbiome to support the discovery of novel immunotherapy agents and biomarkers. There is a growing body of scientific evidence to suggest that the gut...
1 2 3 10

Nyheder

Lundbeckfonden vil dække universiteters projektrelaterede indirekte omkostninger
10. december 2018
Danske forskere: Patientforsøg med stamceller mod diabetes nærmer sig
10. december 2018
Professor søges!
5. december 2018

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge